Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTHOUSE: Brexpiprazole in Acute Schizophrenia
NCT01810380Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Mar 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole orally disintegrating tablet in schizophrenia (3 arms), sponsored by Lundbeck. Primary endpoint: Positive and Negative Syndrome Scale Total Score at 6 weeks. Started Mar 2013; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01810380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01810380.